REVENUE (Tables)

12 Months Ended

Oct. 31, 2024

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Year Ended October 31, 2024:
Americas	$	995	$	674	$	904	$	2,573
Europe	811		452		507		1,770
Asia Pacific	1,409		518		240		2,167
Total	$	3,215	$	1,644	$	1,651	$	6,510

Year Ended October 31, 2023:
Americas	$	1,099	$	634	$	999	$	2,732
Europe	851		417		486		1,754
Asia Pacific	1,560		517		270		2,347
Total	$	3,510	$	1,568	$	1,755	$	6,833

Year Ended October 31, 2022:
Americas	$	1,109	$	567	$	1,006	$	2,682
Europe	844		382		473		1,699
Asia Pacific	1,677		503		287		2,467
Total	$	3,630	$	1,452	$	1,766	$	6,848

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


		Years Ended October 31,
		2024		2023		2022
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical		$	2,242	2,433		$	2,515
Chemicals and Advanced Materials		1,495		1,543		1,521
Diagnostics and Clinical		964		966		963
Food		592		628		617
Academia and Government		567		601		576
Environmental and Forensics		650		662		656
Total		$	6,510	$	6,833	$	6,848

Revenue by Type
Instrumentation		$	2,354	2,742		$	2,907
Non-instrumentation and other		4,156		4,091		3,941
Total		$	6,510	$	6,833	$	6,848

Contract with Customer, Asset and Liability

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2023 and 2024:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2022	$	557

Net revenue deferred in the period	488
Revenue recognized that was included in the contract liability balance at the beginning of the period	(409)
Change in deferrals from customer cash advances, net of revenue recognized	(28)

Currency translation and other adjustments	8
Ending balance as of October 31, 2023	$	616
Net revenue deferred in the period	469
Revenue recognized that was included in the contract liability balance at the beginning of the period	(448)
Change in deferrals from customer cash advances, net of revenue recognized	(9)
Contract liabilities acquired in business combinations	70
Currency translation and other adjustments	3
Ending balance as of October 31, 2024	$	701